2025 Q4 -tulosraportti
Vain PDF
3 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 492 | - | - | ||
| 1 600 | - | - | ||
| 4 500 | - | - | ||
| 7 408 | - | - | ||
| 5 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·31 min sittenTHE BIGGEST PARADIGM SHIFT IN MODERN MEDICINE: What do we actually own? 🧬🌍 Let's put Friday's ticker noise aside for a moment. Far too many here are blindly staring at small penny fluctuations without understanding the fundamental disruptive power in what we actually possess. This is not yet another mediocre biotech company crossing its fingers for a bit of luck in the lab. We own the patents to what could become "Version 2.0" of the entire global RNA industry. To understand how insane this is, we need to look at the problem the industry is struggling with today. Moderna and Pfizer changed the world when they taught the body to produce its own medicine via mRNA. But the technology has a fatal weakness: Ordinary mRNA is linear. This means that the body's own defense mechanisms cut it to pieces in record time. It's like a sparkler – it shines intensely, but goes out almost before it has begun. If one is to treat serious cancer or chronic conditions, an engine that chokes after a few hours simply isn't enough. This is where Circio and the circVec platform come in as the gamechanger of all time. By closing the RNA strand in a circle, there are no ends that enzymes in the body can attack. The result is brutally effective. The cell is transformed into a biological factory that pumps out vital medicine for weeks, perhaps months, instead of hours. We are literally talking about going from a cheap AA battery to a nuclear reactor inside the body's own cells. Once you understand this, you realize that the application area for such a perpetual motion machine is almost limitless. Think of genetic diseases where children lack essential proteins from birth. Instead of a lifetime chained to the hospital chair for constant infusions, circular RNA can program the body to produce the missing protein itself. Think cancer treatment, where the immune system receives a continuous and unstoppable update on exactly which tumors are to be hunted down and crushed. We are talking about everything from future super-vaccines, to being able to restart the production of proteins the body stops making when we age. This is why global giants like Acuitas – the very brain behind the lipid technology for the Pfizer vaccine – are knocking on our door and entering partnerships. Big Pharma knows that the future is circular. They are desperately hunting for the technology that gives them the throne in next-generation medicine, and Circio holds the keys. We have shots on goal in markets worth hundreds of billions. Whether the breakthrough happens within rare diseases, cancer, or vaccines first, is totally irrelevant to us. When our platform is seriously validated by a major industry agreement, today's pricing will just be a comical footnote in the history books. We know exactly what we own. ♟️🧱🍷
·1 t sittenIf one goes to Circios' homepages and selects media and events, there are several events in the near future. There could be a lot of exciting news for us optimists, all the way until August. The share price is under heavy attack from all possible speculators, the essential thing is what the company communicates, and mcap. All the fuss about shorting is noise. Here it's smart to have a stake, I think.
·1 t sittenIt is actually paradoxical and regrettable that the news about Acuitas was completely dismissed and ignored. An “evaluation agreement” means that they are testing something together in laboratory / preclinical studies. Acuitas and Circio will test a combination of their technologies. Circio's circVec (circular RNA, which can provide more stable and potent gene activity), and Acuitas' LNP-platform (lipid nanoparticles), which can deliver RNA into cells, especially T-cells. Acuitas is a validated, tested, and proven standard delivery technology. “Acuitas Therapeutics (CAR-T), the LNP delivery company behind the Pfizer-BioNTech COVID-19 vaccine” Let's just assume that Circio and Acuitas get a real partnership, then it can significantly increase the entire platform's commercial value! Already in the loop: Japanese United Immunity, with whom Circio partnered earlier this year, specializes in P-LNP / Targeted LNP. A cell-precise delivery platform for circVec, with higher efficacy/risks. Circio will thereby get 2 delivery platforms for their circVec technology! 1. Standard validated delivery from Acuitas. 2. Precise high risk/high reward delivery from United Immunity. Circio will be incredibly strong, towards getting their entire platform validated in primates and later humans. 2 important partnerships also strengthen the acquisition possibility from Big Pharma before validation.
·39 min sittenGood reflections and very exciting what's happening going forward. But you are a bit funny, Djensens, you come with good posts, arguments and info when it rose well, close your profile and come with the opposite after having sold. And most who foresaw/wished the price down hit well, but it became a bit too excessive a decline, so it was also a bit coincidental that it dropped so hard and fast. Now you're in again, probably at a slightly higher price than you hoped for, open profile and the positive talk is starting, so let's hope it rises even more than last time. You are at least no better than the other bulls in here, but no hard feelings🤗 There's always room for bullish sentiment and bearish sentiment, just good to be aware of who and when one should relate to them.
·2 t sittenWill Monday be a downturn?
·23 min sittenIt is not unlikely, with so much news in the pipeline. But forget about 10.8 as such; It was a stunt that turned out well for the company, but bad for the shareholders (from 14,- to 5.80) I myself believe it can easily see the ten-kroner mark again quite quickly
·3 t sittenI myself am an investor in the stock, but remember that everyone can have a hidden self-interest.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
3 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·31 min sittenTHE BIGGEST PARADIGM SHIFT IN MODERN MEDICINE: What do we actually own? 🧬🌍 Let's put Friday's ticker noise aside for a moment. Far too many here are blindly staring at small penny fluctuations without understanding the fundamental disruptive power in what we actually possess. This is not yet another mediocre biotech company crossing its fingers for a bit of luck in the lab. We own the patents to what could become "Version 2.0" of the entire global RNA industry. To understand how insane this is, we need to look at the problem the industry is struggling with today. Moderna and Pfizer changed the world when they taught the body to produce its own medicine via mRNA. But the technology has a fatal weakness: Ordinary mRNA is linear. This means that the body's own defense mechanisms cut it to pieces in record time. It's like a sparkler – it shines intensely, but goes out almost before it has begun. If one is to treat serious cancer or chronic conditions, an engine that chokes after a few hours simply isn't enough. This is where Circio and the circVec platform come in as the gamechanger of all time. By closing the RNA strand in a circle, there are no ends that enzymes in the body can attack. The result is brutally effective. The cell is transformed into a biological factory that pumps out vital medicine for weeks, perhaps months, instead of hours. We are literally talking about going from a cheap AA battery to a nuclear reactor inside the body's own cells. Once you understand this, you realize that the application area for such a perpetual motion machine is almost limitless. Think of genetic diseases where children lack essential proteins from birth. Instead of a lifetime chained to the hospital chair for constant infusions, circular RNA can program the body to produce the missing protein itself. Think cancer treatment, where the immune system receives a continuous and unstoppable update on exactly which tumors are to be hunted down and crushed. We are talking about everything from future super-vaccines, to being able to restart the production of proteins the body stops making when we age. This is why global giants like Acuitas – the very brain behind the lipid technology for the Pfizer vaccine – are knocking on our door and entering partnerships. Big Pharma knows that the future is circular. They are desperately hunting for the technology that gives them the throne in next-generation medicine, and Circio holds the keys. We have shots on goal in markets worth hundreds of billions. Whether the breakthrough happens within rare diseases, cancer, or vaccines first, is totally irrelevant to us. When our platform is seriously validated by a major industry agreement, today's pricing will just be a comical footnote in the history books. We know exactly what we own. ♟️🧱🍷
- ·1 t sittenIf one goes to Circios' homepages and selects media and events, there are several events in the near future. There could be a lot of exciting news for us optimists, all the way until August. The share price is under heavy attack from all possible speculators, the essential thing is what the company communicates, and mcap. All the fuss about shorting is noise. Here it's smart to have a stake, I think.
- ·1 t sittenIt is actually paradoxical and regrettable that the news about Acuitas was completely dismissed and ignored. An “evaluation agreement” means that they are testing something together in laboratory / preclinical studies. Acuitas and Circio will test a combination of their technologies. Circio's circVec (circular RNA, which can provide more stable and potent gene activity), and Acuitas' LNP-platform (lipid nanoparticles), which can deliver RNA into cells, especially T-cells. Acuitas is a validated, tested, and proven standard delivery technology. “Acuitas Therapeutics (CAR-T), the LNP delivery company behind the Pfizer-BioNTech COVID-19 vaccine” Let's just assume that Circio and Acuitas get a real partnership, then it can significantly increase the entire platform's commercial value! Already in the loop: Japanese United Immunity, with whom Circio partnered earlier this year, specializes in P-LNP / Targeted LNP. A cell-precise delivery platform for circVec, with higher efficacy/risks. Circio will thereby get 2 delivery platforms for their circVec technology! 1. Standard validated delivery from Acuitas. 2. Precise high risk/high reward delivery from United Immunity. Circio will be incredibly strong, towards getting their entire platform validated in primates and later humans. 2 important partnerships also strengthen the acquisition possibility from Big Pharma before validation.·39 min sittenGood reflections and very exciting what's happening going forward. But you are a bit funny, Djensens, you come with good posts, arguments and info when it rose well, close your profile and come with the opposite after having sold. And most who foresaw/wished the price down hit well, but it became a bit too excessive a decline, so it was also a bit coincidental that it dropped so hard and fast. Now you're in again, probably at a slightly higher price than you hoped for, open profile and the positive talk is starting, so let's hope it rises even more than last time. You are at least no better than the other bulls in here, but no hard feelings🤗 There's always room for bullish sentiment and bearish sentiment, just good to be aware of who and when one should relate to them.
- ·2 t sittenWill Monday be a downturn?·23 min sittenIt is not unlikely, with so much news in the pipeline. But forget about 10.8 as such; It was a stunt that turned out well for the company, but bad for the shareholders (from 14,- to 5.80) I myself believe it can easily see the ten-kroner mark again quite quickly
- ·3 t sittenI myself am an investor in the stock, but remember that everyone can have a hidden self-interest.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 492 | - | - | ||
| 1 600 | - | - | ||
| 4 500 | - | - | ||
| 7 408 | - | - | ||
| 5 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
3 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·31 min sittenTHE BIGGEST PARADIGM SHIFT IN MODERN MEDICINE: What do we actually own? 🧬🌍 Let's put Friday's ticker noise aside for a moment. Far too many here are blindly staring at small penny fluctuations without understanding the fundamental disruptive power in what we actually possess. This is not yet another mediocre biotech company crossing its fingers for a bit of luck in the lab. We own the patents to what could become "Version 2.0" of the entire global RNA industry. To understand how insane this is, we need to look at the problem the industry is struggling with today. Moderna and Pfizer changed the world when they taught the body to produce its own medicine via mRNA. But the technology has a fatal weakness: Ordinary mRNA is linear. This means that the body's own defense mechanisms cut it to pieces in record time. It's like a sparkler – it shines intensely, but goes out almost before it has begun. If one is to treat serious cancer or chronic conditions, an engine that chokes after a few hours simply isn't enough. This is where Circio and the circVec platform come in as the gamechanger of all time. By closing the RNA strand in a circle, there are no ends that enzymes in the body can attack. The result is brutally effective. The cell is transformed into a biological factory that pumps out vital medicine for weeks, perhaps months, instead of hours. We are literally talking about going from a cheap AA battery to a nuclear reactor inside the body's own cells. Once you understand this, you realize that the application area for such a perpetual motion machine is almost limitless. Think of genetic diseases where children lack essential proteins from birth. Instead of a lifetime chained to the hospital chair for constant infusions, circular RNA can program the body to produce the missing protein itself. Think cancer treatment, where the immune system receives a continuous and unstoppable update on exactly which tumors are to be hunted down and crushed. We are talking about everything from future super-vaccines, to being able to restart the production of proteins the body stops making when we age. This is why global giants like Acuitas – the very brain behind the lipid technology for the Pfizer vaccine – are knocking on our door and entering partnerships. Big Pharma knows that the future is circular. They are desperately hunting for the technology that gives them the throne in next-generation medicine, and Circio holds the keys. We have shots on goal in markets worth hundreds of billions. Whether the breakthrough happens within rare diseases, cancer, or vaccines first, is totally irrelevant to us. When our platform is seriously validated by a major industry agreement, today's pricing will just be a comical footnote in the history books. We know exactly what we own. ♟️🧱🍷
- ·1 t sittenIf one goes to Circios' homepages and selects media and events, there are several events in the near future. There could be a lot of exciting news for us optimists, all the way until August. The share price is under heavy attack from all possible speculators, the essential thing is what the company communicates, and mcap. All the fuss about shorting is noise. Here it's smart to have a stake, I think.
- ·1 t sittenIt is actually paradoxical and regrettable that the news about Acuitas was completely dismissed and ignored. An “evaluation agreement” means that they are testing something together in laboratory / preclinical studies. Acuitas and Circio will test a combination of their technologies. Circio's circVec (circular RNA, which can provide more stable and potent gene activity), and Acuitas' LNP-platform (lipid nanoparticles), which can deliver RNA into cells, especially T-cells. Acuitas is a validated, tested, and proven standard delivery technology. “Acuitas Therapeutics (CAR-T), the LNP delivery company behind the Pfizer-BioNTech COVID-19 vaccine” Let's just assume that Circio and Acuitas get a real partnership, then it can significantly increase the entire platform's commercial value! Already in the loop: Japanese United Immunity, with whom Circio partnered earlier this year, specializes in P-LNP / Targeted LNP. A cell-precise delivery platform for circVec, with higher efficacy/risks. Circio will thereby get 2 delivery platforms for their circVec technology! 1. Standard validated delivery from Acuitas. 2. Precise high risk/high reward delivery from United Immunity. Circio will be incredibly strong, towards getting their entire platform validated in primates and later humans. 2 important partnerships also strengthen the acquisition possibility from Big Pharma before validation.·39 min sittenGood reflections and very exciting what's happening going forward. But you are a bit funny, Djensens, you come with good posts, arguments and info when it rose well, close your profile and come with the opposite after having sold. And most who foresaw/wished the price down hit well, but it became a bit too excessive a decline, so it was also a bit coincidental that it dropped so hard and fast. Now you're in again, probably at a slightly higher price than you hoped for, open profile and the positive talk is starting, so let's hope it rises even more than last time. You are at least no better than the other bulls in here, but no hard feelings🤗 There's always room for bullish sentiment and bearish sentiment, just good to be aware of who and when one should relate to them.
- ·2 t sittenWill Monday be a downturn?·23 min sittenIt is not unlikely, with so much news in the pipeline. But forget about 10.8 as such; It was a stunt that turned out well for the company, but bad for the shareholders (from 14,- to 5.80) I myself believe it can easily see the ten-kroner mark again quite quickly
- ·3 t sittenI myself am an investor in the stock, but remember that everyone can have a hidden self-interest.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 492 | - | - | ||
| 1 600 | - | - | ||
| 4 500 | - | - | ||
| 7 408 | - | - | ||
| 5 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt